Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis

• Published in: European journal of endocrinology Vol. 190; no. 6; pp. 467 - 478
• Main Authors: Zhang, Dongyun, Hugo, Willy, Bergsneider, Marvin, Wang, Marilene B, Kim, Won, Han, Karam, Vinters, Harry V, Heaney, Anthony P
• Format: Journal Article
• Language: English
• Published: England 05-06-2024
• Subjects: Adult; Cabergoline - pharmacology; Cabergoline - therapeutic use; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - metabolism; Dopamine Agonists - pharmacology; Dopamine Agonists - therapeutic use; Female; Fibrosis; Humans; Male; Middle Aged; Pituitary Neoplasms - drug therapy; Pituitary Neoplasms - metabolism; Pituitary Neoplasms - pathology; Prolactin - metabolism; Prolactinoma - drug therapy; Prolactinoma - metabolism; Stromal Cells - drug effects; Stromal Cells - metabolism; Tumor Microenvironment - drug effects; Young Adult; prolactinomas; scRNA-seq; cabergoline; tumor microenvironment; pituitary tumor
• ISSN: 0804-4643; 1479-683X; 1479-683X
• DOI: 10.1093/ejendo/lvae055

Unravel the potential mechanism(s) of the on- and off-target actions of dopamine agonist therapy in both human prolactinoma tumors and neighboring stromal and immune cells.
Five surgically resected prolactinomas (PRLomas) from 3 cabergoline (CBG)-treated patients and 2 treatment-naive patients were analyzed by using single-cell RNA sequencing (scRNA-seq) to compare the cellular composition and transcriptional landscape.
Six major cell populations, namely tumor (88.2%), immune (5.6%), stromal (4.9%), progenitor cells (0.6%), proliferating cells (0.4%), and erythrocytes (0.2%), were observed. Tumor cells from CBG-treated patients expressed lower levels of genes that regulated hormone secretion, such as SCG2, VGF, TIMP1, NNAT, and CALD1, consistent with the inhibitory effects of CBG on hormone processing and secretion. Interestingly, we also observed an increased number of CD8+ T cells in the CBG-treated tissues. These cytotoxic CD8+ T cells expressed killing granule components such as perforin and the granzymes GZMB, GNLY, and KLRD1 as well as the inflammatory cytokine CCL5. Immune cell activation of these CD8+ T cells was further analyzed in a compartment-specific manner, and increased CD25 (IL2R) expression was noted in the CD8+ T cells from the CBG-treated samples. Additionally, and confirming prior reports, we noted a higher stromal cell population in the CBG-treated samples.
Our scRNA-seq studies revealed key differences in the transcriptomic features of CBG-treated and CBG-untreated PRLomas in both tumor and microenvironment cellular constituents, and for the first time, describe the previously unknown activation of CD8+ T cells following CBG treatment, which may play a role in the tumoricidal actions of CBG.